Overview

Evaluation of 89Zr-TLX250 PET/CT in Chinese Patients With Indeterminate Renal Masses or Suspected Recurrent Renal Clear Cell Carcinoma

Status:
Not yet recruiting

Trial end date:
2024-04-24

Target enrollment:

Participant gender:

Summary

The study is designed to evaluate the safety, tolerability, radiation dosimetry and pharmacokinetics 89Zr-TLX250 (also known as 89Zr-DFO-girentuximab) Positron Emission Tomography/Computed Tomography (PET/CT) in adult Chinese patients with indeterminate renal masses or Suspected Recurrent Renal Clear Cell Carcinoma

Phase:

Phase 1

Details

Lead Sponsor:

Telix International Pty Ltd

Collaborator:

Grand Pharmaceutical (China) Co., Ltd.